| Literature DB >> 32366884 |
Carlos Pinzon-Arteaga1,2, Matthew D Snyder1, Cicera R Lazzarotto3, Nicolas F Moreno1, Rytis Juras4, Terje Raudsepp4, Michael C Golding1, Dickson D Varner5, Charles R Long6.
Abstract
Phenotypic selection during animal domestication has resulted in unwanted incorporation of deleterious mutations. In horses, the autosomal recessive condition known as Glycogen Branching Enzyme Deficiency (GBED) is the result of one of these deleterious mutations (102C > A), in the first exon of the GBE1 gene (GBE1102C>A). With recent advances in genome editing, this type of genetic mutation can be precisely repaired. In this study, we used the RNA-guided nuclease CRISPR-Cas9 (clustered regularly-interspaced short palindromic repeats/CRISPR-associated protein 9) to correct the GBE1102C>A mutation in a primary fibroblast cell line derived from a high genetic merit heterozygous stallion. To correct this mutation by homologous recombination (HR), we designed a series of single guide RNAs (sgRNAs) flanking the mutation and provided different single-stranded donor DNA templates. The distance between the Cas9-mediated double-stranded break (DSB) to the mutation site, rather than DSB efficiency, was the primary determinant for successful HR. This framework can be used for targeting other harmful diseases in animal populations.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32366884 PMCID: PMC7198616 DOI: 10.1038/s41598-020-62723-3
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Experimental design for the correction of the GBE1C>A mutation in primary equine fibroblasts. A skin biopsy from a GBE1C>A heterozygous high genetic merit American Quarter Horse stallion was used to establish a primary fibroblast cell line. Different sgRNAs at varying distances from the mutation were designed and cloned into the CRISPR-Cas9 PX458 plasmid, which allowed for GFP selection via flow cytometry. Different single-stranded oligodeoxynucleotide (ssODN) repair templates were tested. Cells were co-transfected with the PX458 plasmid and the repair template. Cells were subsequently enriched by flow cytometry and single-cell colonies were recovered. The target region was sequenced for verification of the genetic correction.
Figure 2CRISPR-Cas9 Targeting of GBE1 locus in Primary Horse Fibroblasts. (A) Normal 64XY karyotype of the isolated equine primary fibroblasts. (B) Bright-field and (C) Fluorescent images 12 h after transfection. (D) Fluorescent activated cell sorting (FACS) enrichment of GFP+ cells. (E) Bright-field and (F) Fluorescent images of single-cells 48 h after sorting. (G) Single cell colony 11 days after sorting, (H) Coomassie blue stained colonies 15 days after sorting. (I) Effect of ROCK inhibitor Y27632 on cell viability post-sorting. (J) Schematic illustration of the different sgRNAs used to target the GBE1102C>A mutation. The C to A mutation at base 102 is indicated in red, the red arrow indicates the location of Cas9-mediated DSB 3 bp upstream of the PAM of the designed guides (i,e. +44, +15, +1, −1, −13) (K) Insertions or deletions (INDELS) generated using the designed sgRNAs. Bars represent standard deviation (SD) among biological replicates. Kruskal-Wallis One-way ANOVA with Tukey’s HSD, adjusted value (p) p < 0.001 shown as **p < 0.001 shown as ***p < 0.0001 shown as ****.
Distal sgRNAs with and without a (100-30) ssODN.
| sgRNA | +(100- 30) ssODN RT | −(100- 30) ssODN RT | ||||
|---|---|---|---|---|---|---|
| n Sequenced | % INDELS | % HR | n Sequenced | % INDELS | % HR | |
| +44 | 16 | 18.8a | 0.0 | 12 | 8.3a | 0.0 |
| +15 | 33 | 81.8b | 0.0 | 28 | 85.7b | 0.0 |
| −13 | 19 | 15.8a | 0.0 | 16 | 18.8a | 0.0 |
Table comparing the results of distal sgRNAs with (+ssODN RT) and without (+ssODN RT) a 100-30 single-stranded oligonucleotide (ssODN). The sgRNA describes the location of the cutting site with respect of the mutation location (0), + indicates upstream or 5′ and - indicates downstream or 3′. The percent of INDELS was calculated as the number of sequenced colonies that showed insertions or deletions in the chromatograph analysis divided by the total number of sequenced colonies. The percent of HR was calculated as the number of sequenced colonies that did not presented a double peak in the mutation site and did not had any observable alteration in the chromatograph analysis divided by the total number of sequenced colonies. Values with different subscripts are different by chi-square test (P < 0.05).
RS-1 and SCR7 effect on sgRNA +15 with a (100-30) ssODN.
| Treatment | n Sequenced | % INDELS | % HR |
|---|---|---|---|
| No Compound | 33 | 81.8 | 0.0 |
| 15 µM RS-1 | 36 | 86.1 | 0.0 |
| 80 µM SCR7 | 43 | 79.1 | 0.0 |
| Combined | 43 | 81.0 | 0.0 |
Comparisons of the RAD-51 stimulatory compound RS-1 and the DNA-Ligase IV inhibitory compound SCR7 or their combination when using sgRNA+15 a ssODN. The percent of INDELS was calculated as the number of sequenced colonies that showed insertions or deletions in the chromatograph analysis divided by the total number of sequenced colonies. No HR positive colonies were obtained. No differences were observed between treatment groups using a chi-square test (P < 0.05).
Figure 3Gene editing outcomes of proximal sgRNAs. (A) Total events with modifications showing the percent of INDELS and HR of proximal sgRNAs (+1, −1), and their truncated versions (+1T, −1T) with an asymmetric (67-30) PS-ssODN. Chi-square test (P > 0.05). (B) Sanger sequencing chromatograms of control unmodified colony: red arrow indicates the double peak showing the C (blue) to A (green) conversion in one of the alleles, representing the heterozygous state of the horse. (C) Representative chromatogram of gene-edited single-cell clone. Note there is an absence of the double peak observed in the control colony and the height of the both adjacent cytosines read peaks is approximately the same, indicating the correction of the mutation in the mutated allele. (D) Next generation sequencing (NGS) results of a subset of corrected clones and control mapping to the wildtype allele (Error bars represent SD among sequencing probes). (E) Genomic locations of the three off-target loci for guides +1, −1 and their truncated versions analyzed by NGS. Coding regions were prioritized.
Proximal sgRNAs with and without a (67-30) PS-ssODN.
| sgRNA | +(67-30) PS-ssODN | −(67-30) PS-ssODN | ||||
|---|---|---|---|---|---|---|
| n Sequenced | % INDELS | % HR | n Sequenced | % INDELS | % HR | |
| +1 | 20 | 35.0 | 15.0 | 21 | 33.3 | 0.0 |
| +1T | 23 | 30.4 | 4.3 | 7 | 57.1 | 0.0 |
| −1 | 13 | 23.1 | 15.4 | 8 | 37.5 | 0.0 |
| −1T | 16 | 46.6 | 12.5 | 12 | 41.7 | 0.0 |
Comparisons of INDELS and HR frequencies between cells treated with proximal sgRNAs with and without an asymmetric (67-30) PS-ssODN. The sgRNA describes the location of the cutting site with respect of the mutation location (0), + indicates upstream or 5′ and − indicates downstream or 3′. Truncated (17 nt) sgRNAs are represented by a (T). The percent of INDELS was calculated as the number of sequenced colonies that showed insertions or deletions in the chromatograph analysis divided by the total number of sequenced colonies. The percent of HR was calculated as the number of sequenced colonies that did not presents a double peak in the mutation site and did not exhibit any observable alteration in the chromatograph analysis divided by the total number of sequenced colonies. No differences were observed between treatment groups using a chi-square test (P = 0.28).